Valuation: Cerus Corporation

Market Cap 455M 408M 380M 345M 648M 43.33B 653M 4.56B 1.78B 22.49B 1.71B 1.67B 72.09B P/E 2026 *
-64.6x
P/E 2027 * -226x
Enterprise Value 460M 413M 384M 349M 655M 43.81B 660M 4.61B 1.8B 22.74B 1.73B 1.69B 72.88B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 1.63x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day-0.88%
1 week-4.27%
Current month-5.88%
1 month-10.04%
3 months-27.51%
6 months+16.67%
Current year+8.74%
1 week 2.2
Extreme 2.2
2.33
1 month 2.2
Extreme 2.2
2.69
Current year 1.62
Extreme 1.62
3.47
1 year 1.38
Extreme 1.38
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 01/07/2026
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 16/03/2026
Director/Board Member 72 24/03/2014
Director/Board Member 51 01/07/2026
Date Insider Type Main position Quantity % Market Cap. Importance
17/8/26 Sell

General Counsel

-30,000 0.0150%
16/7/26 Sell

Chief Executive Officer

-16,666 0.0083%
1/7/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%-4.27%+43.59%+73.64% 455M
+0.35%+4.90%-21.62%+13.32% 178B
+1.31%+8.20%-1.41%+30.95% 119B
-0.33%+1.23%-22.83%+9.21% 108B
+1.23%+0.95%-46.07%-9.75% 75.27B
+1.84%+6.26%+6.05%+77.89% 62.99B
+0.34%+0.40%+16.65%+62.51% 53.46B
+0.81%+4.76%+1.19%-26.98% 51.04B
+1.67%+2.64%-16.47%+24.13% 40.99B
-1.87%+0.10%+28.02%+9.56% 32.1B
Average +0.44%+1.94%-1.29%+26.45% 72.12B
Weighted average by Cap. +0.62%+3.15%-11.61%+20.12%

Financials

2026 *2027 *
Net sales 249M 223M 208M 189M 354M 23.69B 357M 2.5B 975M 12.3B 935M 915M 39.42B 272M 243M 226M 206M 386M 25.83B 389M 2.72B 1.06B 13.41B 1.02B 997M 42.98B
Net income -8.77M -7.86M -7.31M -6.65M -12.48M -834M -12.58M -87.85M -34.33M -433M -32.91M -32.2M -1.39B -1.67M -1.49M -1.39M -1.26M -2.37M -159M -2.39M -16.7M -6.53M -82.31M -6.26M -6.12M -264M
Net Debt 5M 4.48M 4.17M 3.79M 7.12M 476M 7.17M 50.11M 19.58M 247M 18.77M 18.36M 791M -13M -11.66M -10.84M -9.86M -18.5M -1.24B -18.65M -130M -50.9M -642M -48.8M -47.75M -2.06B
Projected Income Statement - Annual - Cerus Corporation
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
14/10/26 USD 2.240 -0.88% 2,890,282
13/10/26 USD 2.260 0.00% 2,293,133
12/10/26 USD 2.260 -1.74% 1,179,807
09/10/26 USD 2.300 +0.88% 787,967
08/10/26 USD 2.280 -0.44% 2,419,512
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cerus Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.260USD
Average target price
5.125USD
Spread / Average Target
+126.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerus Corporation
  1. Stock Market
  2. Stocks
  3. CERS Stock